DARE Daré Bioscience, Inc.

NASDAQ

$0.78

Daré Bioscience, Inc. (DARE) is expected to report earnings on November 12, 2026, after the market close. The consensus earnings estimate is a loss of $0.09 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -50.0% since its last earnings release on August 13, 2026.

Daré Bioscience Beat Consensus Estimates

Thursday, August 13, 2026 · 4:01 PM ET

3rd Quarter, Sep 2026

Thursday · 4:00 PM ET

Earnings Whisper

-

vs ($0.09)

Rev est $5.9M

Volatility

Enter your expectations below to reveal the current volatility.

Trend Analysis

Expectation

Earnings

Price action

Signals

Score

Sentiment

Grade

Life Cycle

Call Analysis

Earnings-AVWAP $0.84

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Daré Bioscience, Inc.

Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s health.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.